Zomedica Pharmaceuticals Corp Stock Shares Owned By Insiders
| ZOM Stock | USD 0.13 0.00 0.00% |
Zomedica Pharmaceuticals Corp fundamentals help investors to digest information that contributes to Zomedica Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Zomedica Stock. The fundamental analysis module provides a way to measure Zomedica Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zomedica Pharmaceuticals stock.
Zomedica | Shares Owned By Insiders |
Zomedica Pharmaceuticals Corp Company Shares Owned By Insiders Analysis
Zomedica Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Zomedica Pharmaceuticals Shares Owned By Insiders | 1.70 % |
Most of Zomedica Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zomedica Pharmaceuticals Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Zomedica Shares Owned By Insiders Driver Correlations
Understanding the fundamental principles of building solid financial models for Zomedica Pharmaceuticals is extremely important. It helps to project a fair market value of Zomedica Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since Zomedica Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Zomedica Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Zomedica Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 1.7% of Zomedica Pharmaceuticals Corp are shares owned by insiders. This is 88.8% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is 83.15% higher than that of the company.
Zomedica Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zomedica Pharmaceuticals' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zomedica Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Zomedica Pharmaceuticals by comparing valuation metrics of similar companies.Zomedica Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.
Zomedica Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Zomedica Pharmaceuticals from analyzing Zomedica Pharmaceuticals' financial statements. These drivers represent accounts that assess Zomedica Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Zomedica Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 35.2M | 84.0M | 293.2M | 159.7M | 196.2M | 206.0M | |
| Enterprise Value | 34.7M | 23.9M | 99.6M | 134.1M | 186.0M | 195.3M |
Zomedica Fundamentals
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.0929 | ||||
| Profit Margin | (2.15) % | ||||
| Operating Margin | (1.48) % | ||||
| Current Valuation | 50.64 M | ||||
| Shares Outstanding | 997.95 M | ||||
| Shares Owned By Insiders | 1.70 % | ||||
| Shares Owned By Institutions | 8.33 % | ||||
| Number Of Shares Shorted | 51.14 M | ||||
| Price To Book | 0.62 X | ||||
| Price To Sales | 4.83 X | ||||
| Revenue | 25.19 M | ||||
| Gross Profit | 13.65 M | ||||
| EBITDA | (29.39 M) | ||||
| Net Income | (34.53 M) | ||||
| Cash And Equivalents | 27.4 M | ||||
| Cash Per Share | 0.19 X | ||||
| Total Debt | 2.73 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 43.50 X | ||||
| Book Value Per Share | 0.24 X | ||||
| Cash Flow From Operations | (15.97 M) | ||||
| Short Ratio | 17.24 X | ||||
| Earnings Per Share | (0.06) X | ||||
| Target Price | 0.25 | ||||
| Number Of Employees | 144 | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 147.6 M | ||||
| Total Asset | 253.2 M | ||||
| Retained Earnings | (170.93 M) | ||||
| Working Capital | 90.85 M | ||||
| Net Asset | 253.2 M |
About Zomedica Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zomedica Pharmaceuticals Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zomedica Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zomedica Pharmaceuticals Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Zomedica Pharmaceuticals Piotroski F Score and Zomedica Pharmaceuticals Altman Z Score analysis. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.06) | Revenue Per Share 0.027 | Quarterly Revenue Growth 0.018 | Return On Assets (0.09) | Return On Equity (0.24) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.